Business Revenue Mix

Click to enlarge

Geographic Revenue Mix

Click to enlarge

Our diversified portfolio includes medical technologies that address many of the world’s most pressing medical conditions.

Sales in emerging markets grew from 9 percent of total sales in FY2011 to 10 percent in FY2012.

38%

Revenue from New Products

FY2012 revenue from products introduced in the past three years.

21%

Growth in Emerging Markets

These include Asia Pacific (except Australia, Japan, Korea, and New Zealand), Central and Eastern Europe, Greater China, Latin America, the Middle East and Africa, and South Asia.

35

Consecutive Years of
Increasing Our Cash Dividend

Which was recognized by our addition to the S&P 500 Dividend Aristocrat Index in December 2011.

Excluding special charges, restructuring charges, net, certain litigation charges, net, certain acquisition-related items, non-cash charge to interest expense due to the accounting rules governing convertible debt, certain tax adjustments, and Physio-Control divestiture-related items.

As reported

5-year CAGR* for diluted earnings per share, as reported 16.2%.

5-year CAGR* for diluted earnings per share, excluding special charges, restructuring charges, net, certain litigation charges, net, certain acquisition-related items, non-cash charge to interest expense due to the accounting rules governing convertible debt, certain tax adjustments, and Physio-Control divestiture-related items 7.4%.